Protocols
Research Stage
Phase 2 and TRIUMPH-1 Phase 3 data show retatrutide's cardiometabolic burden is manageable at 9 mg but clinically meaningful at 12 mg in patients with pre-existing cardiac risk. The glucagon receptor-mediated heart rate increase is the primary signal. No oral formulation exists. The 9 mg dose is the evidence-supported inflection point where efficacy is maximised without disproportionate cardiometabolic cost.
August 5, 2026
·
11 min read
Protocols
Research Stage
In July 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted against recommending BPC-157, TB-500, KPV, and MOTS-c for the 503A bulk drug substances list. The committee cited absent human pharmacokinetic data, unresolved oncological signals for the angiogenic peptides, and no approved human indication for any of the four compounds as the primary evidentiary basis for each negative vote.
August 4, 2026
·
12 min read
Protocols
Research Stage
Rusfertide (PTG-300) is a synthetic hepcidin mimetic that suppresses erythropoiesis by blocking ferroportin-mediated iron export. In the Phase 2 REVIVE trial and the pivotal Phase 3 VERIFY trial, subcutaneous rusfertide eliminated or sharply reduced therapeutic phlebotomy requirements and maintained hematocrit below 45% in most polycythemia vera patients, establishing the strongest human evidence for iron restriction as a cytoreduction-independent disease-control strategy.
August 3, 2026
·
11 min read
Protocols
Research Stage
Gastric acid degrades oral semaglutide through direct acid-catalysed hydrolysis at pH 1 to 3 and through pepsin activation that cleaves semaglutide's backbone before it reaches absorptive epithelium. A 2026 review by Nayak, Dessai, and Nayak identifies acid protection as the central unsolved engineering challenge and proposes novel strategies to overcome it.
July 28, 2026
·
10 min read
Protocols
Research Stage
A 2026 Scientific Reports study and ADA 2026 proteomics data show that semaglutide attenuates cardiac ECM remodelling by restoring gut-barrier integrity and suppressing myocardial collagen deposition in obesity models, while a mortality-trained proteomic clock across SELECT and STEP cohorts found semaglutide 2.4 mg reduced multi-organ biological age by approximately 5.2% — with the largest effects in heart and kidney.
July 28, 2026
·
11 min read
Protocols
Research Stage
The 2026 Yuan review in International Journal of Molecular Sciences identifies three analgesic mechanisms in BPC-157 that operate independently of structural tissue repair: selective eNOS upregulation via the Src–Caveolin-1–eNOS pathway, suppression of TNF-α and IL-6 driving peripheral nociceptor sensitisation, and dose-dependent attenuation of neurogenic pain in formalin Phase 1 — a spinal-level effect separable from local wound healing.
July 27, 2026
·
9 min read